Form 4: Biohaven Executive Kimberly Gentile Reports Stock Transactions

Biohaven's SVP of Clinical Operations, Kimberly Gentile, reported the acquisition of shares and stock options, as well as the disposal of shares to cover tax obligations.

Summary

• Kimberly Gentile, SVP of Clinical Operations at Biohaven, reported several transactions involving the company's stock on January 5, 2025.
• She acquired 3,750 common shares and 91,000 stock options, both at a price of $0.
• Additionally, she received 15,000 restricted share units.
• 1,956 common shares were disposed of at $38.64 per share to cover tax obligations related to the vesting of restricted share units.
• Following these transactions, Ms. Gentile directly owns 97,763 common shares, 91,000 stock options, and 11,250 restricted share units.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and does not indicate any significant positive or negative events. The transactions are routine and expected.

Positives

• The acquisition of 91,000 stock options and 15,000 restricted share units indicates continued alignment of executive interests with the company's performance.
• The vesting schedule of the options and restricted share units encourages long-term commitment from the executive.

Negatives

• The disposal of 1,956 shares, while for tax purposes, reduces the executive's direct shareholding.

Risks

• The vesting of stock options and restricted share units is contingent on the executive's continued service with the company, which could be a risk if there are changes in personnel.
• The tax obligations associated with vesting can lead to share disposals, potentially impacting the executive's overall stake.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and compensation structure.

Comparison to Industry Standards

• Stock option and restricted share unit grants are standard forms of executive compensation in the biotechnology industry, aligning executive interests with company performance.
• The vesting schedules of four equal installments annually are also common practice to encourage long-term commitment.
• The disposal of shares to cover tax obligations is a typical occurrence when restricted stock units vest.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
• The vesting of stock options and restricted share units incentivizes the executive to contribute to the company's long-term success.

Key Dates

Keywords

Biohaven, stock options, restricted share units, insider trading, executive compensation, share disposal, common shares, vesting